Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera (NCT06093672)

🧪 Interventions in This Study

• Givinostat (DRUG)
• Hydroxyurea (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (90 Sites)

Showing the first 25 of 90 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• Emad Ibrahim, MD, Inc — Redlands, California
• US Oncology Inc — Englewood, Colorado
• American Oncology Partners of Maryland, PA — Bethesda, Maryland
• Icahn School of Medicine at Mount Sinai — New York, New York
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• The Cleveland Clinic Foundation — Cleveland, Ohio
• Oncology Associates of Oregon, P.C. — Eugene, Oregon
• MD Anderson Cancer Center — Houston, Texas
• Texas Oncology (Webster) - USOR — Houston, Texas
• Texas Oncology-Denison Cancer Center — Sherman, Texas
• University of Utah - Huntsman Cancer Institute - PPDS — Salt Lake City, Utah
• The James Cancer Hospital and Solove Research Institute — Roanoke, Virginia
• VA Puget Sound Health Care System - NAVREF - PPDS — Seattle, Washington
• Landesklinikum Wiener Neustadt — Wiener Neustadt, Lower Austria
• Medizinische Universitat Wien (Medical University of Vienna) — Vienna, State of Vienna
• Ordensklinikum Linz GmbH Elisabethinen — Linz, Upper Austria
• Klinikum Wels-Grieskirchen GmbH — Wels, Upper Austria
• Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda — Sofia, Sofia-Grad
• University Multiprofile Hospital for Active Treatment Sveti Georgi EAD — Plovdiv,
• University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD — Stara Zagora,
• Clinical Hospital Dubrava — Zagreb, City of Zagreb
• Clinical Hospital Center Rijeka - PPDS — Rijeka,
• Clinical Hospital Center Rijeka — Rijeka,
• General Hospital Sibenik — Šibenik,

📞 Contact the Study Coordinator

Phone: +39 02 6443 1

Email: patientadvocacy@italfarmacogroup.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Polycythemia Vera

• A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Mobile, Alabama
• Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera — Covington, Louisiana
• KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera — Birmingham, Alabama
• Study to Assess SLN124 in Patients With Polycythemia Vera — Hammond, Louisiana
• A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV — Jacksonville, Florida
• A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes — Rochester, Minnesota

Explore by condition: All Polycythemia Vera clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.